Sitagliptin

Sitagliptin (CAS No.: 486460-32-6) is a potent, selective small-molecule inhibitor of dipeptidyl peptidase-4 (DPP-4) widely utilized as a biochemical tool in metabolic and endocrinology research. By competitively inhibiting DPP-4 with high affinity in the nanomolar range, sitagliptin prevents the enzymatic degradation of incretin hormones such as glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, thereby elevating their active levels and modulating downstream signaling pathways associated with glucose homeostasis. In addition to its canonical DPP-4 inhibition, sitagliptin has been reported to influence intracellular signaling cascades, including cAMP/PKA and ERK1/2 pathways, and may promote incretin secretion from intestinal L cells through DPP-4-independent mechanisms. This compound is frequently applied in cell-based assays and animal models to investigate incretin biology, pancreatic islet function, and metabolic regulation, as well as to evaluate protective effects on islet cells under stress conditions. Experimental concentrations or dosing regimens vary depending on specific study designs, typically spanning nanomolar to micromolar ranges in vitro, and are optimized according to the biological system under investigation.